Abstract: Polymedicated neonates and young infants may be at risk of harmful cumulative exposure to toxic excipients like ethanol, propylene glycol and benzyl alcohol during routine clinical care. The aim of this study was to calculate the cumulative daily alcohol exposure (mg/kg/day) in polymedicated neonates and infants and compare these levels to the tolerance limits found in guidelines published by European Medicines Agency (EMA). As part of the SEEN study, all medicinal products administered to neonates and infants were recorded. All included neonates received ≥2 medicinal products/day and infants ≥3 medicinal products/day. Daily excipient levels were calculated based on quantities obtained from manufacturers or databases. Excipient levels were compared to tolerance limits proposed by the EMA. Altogether, 470 neonates and 160 infants were included, recording 4207 prescriptions and 316 products. In total, 45% (n = 288) of patients were exposed to an alcohol of interest; 2% (n = 14) were exposed to benzyl alcohol (BA), 38% (n = 237) to ethanol and 23% (n = 146) to propylene glycol (PG). Of the total number of prescriptions involving ethanol-containing medicinal products (n = 334), 51% would alone exceed tolerance limit of 6 mg/kg/day. Of the total number of prescriptions involving PG-containing medicinal products (n = 174), 70% would alone exceed a maximum tolerance limit of 50 mg/kg/day. Maximal daily exposure to ethanol (1563 mg/kg/day) or PG (954 mg/kg/ day) exceeded the tolerance limits recommended by EMA 260.5 and 19.1 times, respectively. Tolerance limits for ethanol and PG as proposed by the EMA are frequently exceeded in polymedicated neonates and infants due to the cumulative effect of these alcohols. Alternative formulations may minimize excipient exposure.
Medical formulations contain excipients such as additives and solvents to overcome chemical and physical challenges of an active pharmaceutical ingredient (API). However, excipients are not always innocent bystanders [1] . Guidelines on 'acceptable excipient levels in neonates and infants' have been issued by both The Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for example for preservatives such as benzyl alcohol (BA) and solvents such as propylene glycol (PG) and ethanol to avoid toxic excipient exposure [2] [3] [4] [5] [6] [7] . However, many medicinal products licensed prior to the Paediatric Regulation still contain excipients no longer recommended for children [8, 9] . Further, extemporaneous medicinal products are commonly used in the youngest subset, because dosing flexibility is needed. They often contain excipients such as propylene glycol or ethanol to solubilize medicinal products with otherwise limited water solubility [10] .
Hospitalized neonates and infants are typically exposed to numerous distinct medications containing potentially harmful excipients and have a higher risk of excipient-related adverse drug events (ADEs) and excipient-excipient interactions [8] .
Thus, organ immaturity and differences in pharmacokinetic and pharmacodynamic profiles are not limited to the elimination of the API, but also include excipients and additives coadministered with the API [1, [11] [12] [13] [14] . In the adult liver, ethanol, PG and BA are all metabolized by the hepatic enzyme alcohol dehydrogenase (ADH) [12, 13] . The ADH activity in liver is lower in neonates and infants younger than two months of age, being less than 20% of adult levels [12] and do not reach adult activity before the age of 5 years [15] . Further, the metabolic capacity of ADH is limited why it may easily be saturated resulting in zero-order kinetics [16] . Due to the combination of limited metabolic capacity and activity, with all three excipients metabolized by the same enzyme, the risk of accumulation may be higher in these polymedicated neonates and infants [11] [12] [13] . As a result, the toxicity of excipients may, therefore, differ between adult and paediatric patients, as well as across the paediatric subgroups [17] . Recently, the FDA banned the use of an oral solution of lopinavir/ritonavir (Kaletra©) in pre-term neonates and term neonates less than 14 days old. The oral solution contains both ethanol and propylene glycol, which causes higher risk of hyperosmolality, CNS depression, renal toxicity, hypotonia and cardiac arrhythmias. Further, FDA stated that 'the total amounts of ethanol and propylene glycol from all medications that are to be given to paediatric patients from Author for correspondence: Helle Holst, Department of Clinical Pharmacology, Bispebjerg University Hospital, Copenhagen, Denmark (e-mail helle.holst.01@regionh.dk).
14 days to 6 months of age should be considered in order to avoid toxicity from these excipients' [18] .
In neonates and infants, excipient-related ADEs may be difficult to detect due to the complexity of the medical conditions, which may cause symptoms or abnormal findings in blood samples indistinguishable from an ADE [19, 20] . Occasionally, ADEs are more evident and easier to recognize when medical procedures change. In the 1980s, the excipient BA was used in fluids used to flush intravenous catheters of low birthweight infants (LBWI). After change of flush-fluid, a retrospective case-control study found a significant decrease in both mortality rate from 80.7% to 45.7% and in the incidence of grade III/IV intraventricular haemorrhage from 46% to 19% among LBWIs, who were not exposed to the preservative (BA) compared to those who were [21] . In consequence, the administration of medicines containing BA is today contraindicated in neonates and of special concern in infants less than three years of age [5] .
Further, some ADEs affecting physical growth, cognition or organ development may only become evident in long-term follow-up studies [19] . Both ethanol and PG have resulted in, for example, neurotoxic effects later in life due to early-life exposure [12, [22] [23] [24] .
Although the previous issues on BA, PG and ethanol reflect potential harmful exposure to these excipients in neonates and infants, earlier studies have suggested that cumulative excipient exposure is difficult to quantify [1, 8, 9, 25] . Additionally, the result may be influenced by country due to different availability of products without potential harmful excipients.
The aim of the SEEN project 'Safe Excipient Exposure in Neonates and Small Children' was to determine cumulative exposure of selected excipients of interest (EOIs) in neonates and infants. Here, presented as the cumulative daily amounts of BA, ethanol and PG exposure in polymedicated neonates and infants based on available information by manufacturers including extemporaneously prepared medicinal products. These amounts were subsequently compared to tolerance limits found in guidelines published by the EMA [5, [26] [27] [28] [29] .
Materials and Methods
Study design and cohort. The SEEN project is a retrospective, observational, descriptive study conducted as a chart review on neonates, infants and children treated at the highly specialized National Hospital of Copenhagen, Denmark, between 1 February 2006 and 14 February 2016. The study protocol has been previously published [30] . In short, all neonates less than 28 days receiving ≥2 unique medicinal products, and infants between 28 days and 23 months, and children younger than five years of age, receiving ≥3 unique medicinal products, were eligible for inclusion. Patients were included on the day the highest number of unique medicinal products was administered. Patients were only excluded if no weight was registered in the chart review.
Patients were included consecutively from February 2016 and backwards, to ensure the correctness and actuality of the data. They were included for at least 12 consecutive months, hereby covering differences in seasonal variation in diseases and subsequent treatment. The final data analysis covers a two-year period of exposure to ethanol, propylene glycol and benzyl alcohol in neonates and infants less than two years of age hospitalized between the 1 February 2014 and 14 February 2016. The study of children above two years of age and below five years of age will be reported elsewhere. Collection and analysis of additional data from 1 February 2006 to 1 February 2014, as well as data on exposure to parabens and artificial sweeteners, will likewise be presented elsewhere.
Information on excipient quantity was obtained through direct contact with manufacturers, from Summary of Product Characteristics (SmPCs) and restricted databases. Definitions and calculations. Neonates (<28 days), infants (between 28 days and 23 months) and children younger than five years of age were stratified in accordance with International Conference of Harmonization E11 guidelines:'Clinical Investigation of Medicinal Products in the Paediatric Population' [31] .
A unique medicinal product was defined as any product with an ATC code and specific manufacturer, concentration and type of formulation. The following information was recorded: personalized identification number (CPR number), gender, age (both gestational and postnatal age), weight (birthweight and weight at time of inclusion/time of medical product administrations), diagnosis (according to ICD-10 system), pregnancy and birth information (i.e. prematurity, type of delivery), information on medical treatment; medicinal product (generic name and trade name), indication, dosage, interval, type of formulation, route of administration, content of excipients and type of origin.
Excipient exposure was calculated as the daily cumulative level of all excipient administrations on the day of inclusion. The accumulated daily excipient level was compared with the tolerance limits specified in the EMA guideline. The bioavailability of both parenteral and enteral administrations of BA, ethanol and PG was set at 100%. This is in accordance with pharmacokinetic studies by Swift et al. [32] . The daily blood-alcohol content (BAC) was calculated using the formula for theoretical calculation of BAC [26] based on information on excipient quantity in medicinal products. PG added to the BAC with onethird the toxicity of ethanol [33] . In accordance with the EMA guideline, a volume of distribution of 0.6 L/kg was used for all patients [26] . The principle of superposition was used in one case to evaluate the cumulative effect of ethanol and PG-containing medicinal products during 48 hr in the patient with highest calculated daily BAC.
For further discussion of and information on tolerance limit published by the EMA as well as how excipient levels and BAC were calculated, we refer to the 'Data S1'.
Outcomes. The primary outcome was the calculation of the daily level of excipients: ethanol, PG and BA in neonates, infants, and children and calculation of daily BAC.
The secondary outcome was the number of concomitant administrations of excipient of interest in neonates, infants and children.
Statistical analysis. Patients were stratified according to age (neonates, infants and children) and by type of excipient exposure. Descriptive analysis was used for patient characteristics and excipient exposure. Missing values were excluded in the analysis, that is lack of excipient quantities in the formulation, if the patient was premature and gestational age. Skewed baseline characteristics were logarithmically transformed before presentation of mean and standard deviation (S.D.) or median and 95% confidence interval (CI). Skewed data of primary outcomes were reported as median and range. P values below 0.05 were considered significant. The analyses were conducted using the RSoftware version i386 3.3.1 (CRAN) and Microsoft Excel â 2010.
Results

Population Characteristics.
In total, 1204 chart reviews of neonates and infants were screened. Of those, 48% (n = 574) did not meet the inclusion criteria or were duplicates. A final number of 630 patients were included. All patients were less than 2 years of age at the time of inclusion. On the day of inclusion, neonates and infants were treated at either a neonatal, paediatric or an adult unit. The majority of both neonates and infants received five medicinal products or more on the day of inclusion. Gestational age ranged from 22 weeks and six days to 42 weeks. The post-natal age ranged from zero days to 22 months of age, table 1. Demographic data were missing for three neonates and 23 infants on gestational age, two neonates and 16 infants on prematurity and seven neonates and 24 infants on birthweight.
Excipient Information. Altogether, 4207 prescriptions for 316 medicinal products were administered to treat the neonates and infants. 8.8% (n = 28) contained ethanol, 6.0% (n = 19) contained PG and 2.8% (n = 9) contained BA. Data on excipient quantities are missing in five medicinal products containing ethanol (18%), eight containing PG (42%) and one containing BA (11%). Thus, data on daily exposure rates are completely missing in 3% (n = 9) of the patients exposed to one or more EOI (ethanol, BA or PG). Accumulative daily exposure rates are incomplete in 7% (n = 16) of those exposed to ethanol, 12% (n = 17) of those exposed to PG and in 7% (n = 1) of those exposed to BA.
Exposure to BA, Ethanol and PG above tolerance limit. In total, 45% (n = 288) of patients were exposed to an excipient of interest; 2% (n = 14) were exposed to BA, 38% (n = 237) to ethanol and 23% (n = 146) to PG. Eleven of the fourteen patients exposed to BA were also exposed to ethanol and/or PG.
Since BA is contraindicated in neonates and infants below the age of three, all subsets exposed to BA exceeded the tolerance limit. The highest daily exposure was 3.7 mg/kg in neonates and 44.4 mg/kg in infants, see table 1. Further, among all patients exposed to ethanol, 53% of neonates and 62% of infants were exposed to ethanol levels exceeding the tolerance limit levels proposed by EMA. Among all patients exposed to PG, 40% of the neonates and 57% of the infants were exposed to levels above the tolerance limit as proposed by EMA. Further, in the patient subset exposed to ethanol above tolerance limit (n = 134), 57 neonates (70% of neonates exposed above tolerance limit) and 28 infants (53% of infants exposed above tolerance limit) were also concomitantly exposed to PG. Of the patients exposed to PG above tolerance limit (n = 126), 58 neonates (67% of neonates exposed above tolerance limit) and 27 infants (68% of infants exposed above tolerance limit) were also concomitantly exposed to ethanol. For further characteristics of patients exposed to ethanol and PG, see fig. 1 and table 2 .
When analysing the total number of prescriptions involving ethanol-containing medicinal products (n = 334), 51% of these would alone exceed tolerance limit of 6 mg/kg/day. The maximal daily exposure to ethanol was 1563 mg/kg/day or 260.5 times higher than the proposed tolerance limit by the EMA. Similarly, of the total number prescriptions involving PG-containing medicinal products (n = 171), 100% (n = 149) with known PG content would alone exceed tolerance limit of 1 mg/kg/day, 70% of prescriptions (n = 120) would alone exceed tolerance limit of 50 mg/kg/day, while the maximal daily exposure to PG (954 mg/kg/day in an infant) would exceed the tolerance limit recommended by EMA by approximately 19.1 times.
The maximal daily exposure to ethanol and PG over time was calculated using the principle of superposition in one patient. The theoretically calculated daily accumulated BAC was approximately 2.8 per mill, as illustrated in fig. 2A . Moreover, in the same figure, it is evident that the contribution to this high level is mainly due to orally administered morphine and phenobarbital intravenously administered. In fig. 2B , the same treatment regimen was substituted by other available medicinal products without the problematic excipients.
Discussion
Eight years ago, Whittaker et al. [8] reported that pre-term infants were commonly exposed to excipients in oral Number of medicinal products -no. formulations in a neonatal care unit. The same year, Shehab et al. [25] quantified both BA and PG exposure in critically ill neonates and infants. In line with their findings, the present study revealed that 40% of the patients were exposed to ethanol and 25% were exposed to PG, while exposure to BA was rare (2% of all patients).
In this study, we found that polymedicated neonates and infants are at risk of exposure to high levels of BA (up to 44.4 mg/kg/day), ethanol (up to 1563 mg/kg/day) and PG (up to 954 mg/kg/day). These levels correspond to 44.4, 260.5 and 19.1 times the maximal daily intakes proposed by the EMA [29] , respectively. These levels are based on theoretical calculations. However, the approximations are based on excipient quantities obtained through direct contact to manufacturers if not provided in a restricted database, or in the SmPC. Thus, the estimated excipient levels are assumed quite accurate, as excipient quantities are only completely missing in 3% of all patients exposed to one or more excipients of interest. In addition, data were incomplete in 7% (n = 16) of those exposed to ethanol, 12% (n = 17) of those exposed to PG and in 7% (n = 1) of those exposed to BA, respectively. The theoretically calculated excipient levels may differ from levels measured in blood samples, as we estimate the daily accumulative levelnot levels timely related to administrations of excipient-containing medicinal products.
A few studies have measured the actual blood concentrations in neonates treated with ethanol, PG-or BA-containing medicine [2, 25, 34] . The most recent study by Pandya et al. demonstrated that treatment of neonates with medicinal products containing between 0.3-7.7% ethanol did not result in toxicologically relevant ethanol exposure. However, ethanolcontaining medications caused elevation of blood acetaldehyde consistent with moderate alcohol exposure in study subjects compared to controls [34] . In this study, the median sampling time after last dose was 30.8 hr (range 0-321 hr), which might partly explain the low blood-ethanol levels.
In a study by Marek et al., [2] ethanol concentration profiles varied widely after exposure secondary to ethanol-containing medicinal products. Here, approximately one-third of blood-ethanol levels were above the EMA recommendation following a single dose of ethanol-containing medication, although ethanol was eliminated rapidly.
The lack of a pharmacokinetic model to describe ethanol and propylene glycol pharmacokinetics led us to illustrate how ethanol and propylene glycol may accumulate to elevate the BAC by using the principle of superposition. In our calculations, we accounted for the potential excipient-excipient interaction of ethanol and PG, which are both metabolized by alcohol dehydrogenase [12] . Data were drawn from one of the patient chart reviews in this study and illustrated in fig. 2A . The lack of actual blood concentration measurements is an obvious limitation to the present study. However, the simple waterfall chart highlights the need for awareness of both the frequency and the actual dosage of ethanol and PGcontaining medicinal products. It also highlights the limitations of this study, and the study by Pandya et al., [34, 35] which is part of the European Study of Neonatal Excipient Exposure -the ESNEE consortium; both studies primarily focus on the amount of, for example, ethanol and PG in the administered medicinal product, thus not optimally also focusing on the timing of the excipient-containing administrations as predictive of levels of excipient exposure. The latter consortium conducted a comprehensive pan European-based questionnaire and a point prevalence survey of excipient exposure in neonates. In total, they included 726 neonates in 21 countries covering 2095 prescriptions for 530 products Fig. 1 . This figure illustrates the number of patients (neonates and infants, respectively) who are exposed to ethanol and propylene glycol -both concomitantly and alone. Neonates are shown in dark blue and infants in light blue. [36] . In contrast to this study, we calculated the cumulative excipient exposure administered in a population of 630 neonates and infants, almost corresponding to the size included in the study by the ESNEE consortium of 726 neonates.
Additionally, the present study includes twice as many prescriptions (n = 4207), although it is only conducted in one country. Further, this study also included medicinal products administered during more than 12 months were included, thereby limiting seasonal variations. Thus, the present study supplements the findings presented by the ESNEE consortium; neonates and infants are frequently exposed to ethanol and propylene glycol but not benzyl alcohol. In agreement with the ESNEE consortium, blood samples are in our opinion the way forward to evaluate the risk/benefit of administration of medicinal products containing potentially harmful excipients such as BA, ethanol or PG. Such blood samples must cover the whole dosing period. Further, as ethanol has a relatively short half-life in the body, frequent blood samples would be necessary to determine the amount of cumulative exposure [32] . Figure 2B illustrates the effect of such substitution, which might minimize ethanol exposure, as demonstrated in the current case. Neither the FDA nor the EMA has published a guideline, despite reports of health issues on Kaletra â [18] , due to dual exposure to ethanol and PG [18] . In addition, the current limit of 0,5% v/v ethanol set by the FDA only applies to over-the-counter medicinal products for children less than six years of age and not for prescribed medicines [3] . In the present study, all neonates and the majority (70%) of infants would reach tolerance limit of PG after one dosage of a PG-containing medicinal product according to the EMA guideline [29] . Only a few patients were exposed to BA. However, this excipient should be avoided, as levels of exposure to BA were up to 3.7 mg/kg in neonates and 44.4 mg/kg infants, respectively, even though the World Health Organization has set a tolerance limit of 5 mg/kg/day in adults [35] . In recent years, other important initiatives have been promoted in Europe to achieve more knowledge about the potential harmful effect on excipients, herein the establishment of the STEP database (Safety and Toxicity of Excipients for Paediatrics) and the ESNEE Consortium [17, 35] .
Limitations:. The retrospective design is an obvious limitation of the present study. In addition, patients were included by the number of medicinal products and not by the amount of excipient. Exposure to ethanol and PG are minimum estimates, as levels from previous days were not taken into account. Further, no blood-ethanol concentrations were available for the patients included thus not available for authors for comparison with calculated levels. However, ethanol is a small molecule, which is rapidly absorbed by simple diffusion in the stomach (20%) and in the duodenum (80%), respectively [32] . Food content in the stomach lowers the concentration of orally administered excipients by dilution and is more evident for small volumes [32] . Very ill neonates and infants are often parenterally fed, but other factors such as slow gastric emptying may also influence absorption [12] . Moreover, liver impairment and stages of ontogeny may reduce clearance of both ethanol, PG and BA [12] . However, the metabolism of ethanol has been suggested to follow an alternative pathway (the catalase pathway) in neonates and infants compared to adults [16, 37] . As a consequence, ethanol metabolism in neonates and infants may follow first-order kinetics [16] . In this study, we assume a zeroorder kinetic profile of the metabolism of ethanol due to a focus on the potential pharmacokinetic interaction between ethanol, PG and BA in the ADH metabolic pathway.
Thus, theoretical estimations might differ from levels obtained by blood samples due to many different reasons.
Nevertheless, theoretical calculations may be a useful tool to evaluate the risk of daily excipient exposure exceeding proposed tolerance limits. However, more studies are needed to evaluate the actual blood concentrations of ethanol, PG and BA to assess the true exposure levels and the impact of early-life exposure these potentially harmful excipients.
Conclusion
Most polymedicated patients exposed to ethanol above tolerance limit level were also concomitantly exposed to PG.
Pharmacokinetic studies of concomitantly administered excipients metabolized by the same enzyme complex are lacking, as are long-term safety data.
Consequently, product substitution should be considered for ethanol and PG-free medicinal products whenever possible to avoid potentially toxic excipient accumulation. A way forward could be a systematic substitution of these excipients endorsed by the medicines agencies to secure the continuous availability of alternative medicinal products.
